Table 1

Pre-treatment patient characteristics

#

Age

Race

PSA (ng/mL)

T Stage

Gleason Score

Risk Group

Prostate Volume (cc)

AUA

SHIM

1

60

Cau

4.7

1c

3+3

Low

53

3

20

2

69

Cau

6.8

1c

3+4

Intermediate

46

3

14

3

69

Cau

6.1

1c

3+3

Low

29

9

1

4

60

Cau

4.5

1c

3+3

Low

21

3

18

5

71

AA

4.0

1c

2+3

Low

31

16

19

6

72

Cau

5.6

1c

3+3

Low

41

4

1

7

56

AA

5.7

1c

3+3

Low

43

9

16

8

70

Cau

4.9

1c

3+3

Low

23

4

21

9

74

Cau

4.9

1c

3+3

Low

45

10

15

10

78

Cau

8.1

2b

3+3

Intermediate

33

1

3

11

71

Cau

4.9

1c

3+3

Low

33

5

20

12

58

AA

7.9

1c

3+4

Intermediate

37

12

21

13

66

Cau

10.3

1c

3+3

Intermediate

34

14

25

14

74

AA

6.3

1c

4+3

Intermediate

55

9

4

15

70

Cau

6.8

1c

3+3

Low

30

21

20

16

62

Cau

4.0

1c

3+4

Intermediate

30

1

25

17

79

Cau

2.3

2b

3+4

Intermediate

52

5

3

18

48

AA

6.8

1c

3+3

Low

18

8

24

19

73

Cau

6.9

1c

3+4

Intermediate

40

3

4

20

62

Cau

5.6

1c

3+3

Low

25

6

23

21

63

AA

6.2

1c

3+4

Intermediate

42

4

15

22

69

AA

5.8

1c

3+4

Intermediate

42

6

18

23

71

AA

5.9

1c

3+3

Low

34

2

24

24

65

Cau

7.4

1c

4+3

Intermediate

33

7

24

25

78

AA

4.2

2b

4+3

Intermediate

37

10

1

26

67

Cau

4

2a

3+3

Low

49

5

20

Abbreviations: Cau - Caucasian; AA - African American; AUA - American Urology Association; SHIM - sexual health inventory for men.

Oermann et al. Journal of Hematology & Oncology 2011 4:12   doi:10.1186/1756-8722-4-12